查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2085387

梭菌疫苗市場：2026-2032年全球市場預測（按疫苗類型、目標疾病、給藥途徑、通路和最終用戶分類）

Clostridium Vaccine Market by Vaccine Type, Target Disease, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，梭菌疫苗市場將成長至 10.591 億美元，複合年成長率為 7.31%。

主要市場統計數據
基準年 2025 6.1379億美元
預計年份：2026年 6.602億美元
預測年份 2032 1,005,910,000 美元
複合年成長率 (%) 7.31%

梭菌疫苗市場處於動物健康、人類免疫、食品安全和合理使用抗菌藥物的交匯點。主要產品包括針對牲畜中梭狀芽孢桿菌（Clostridium chauvoei）、產氣莢膜梭菌（Clostridium perfringens）、敗血梭菌（Clostridium septicum）、諾維梭菌（Clostridium novyi）、索氏梭菌（Clostridium 這些梭狀梭菌）、破傷風梭菌（Clostrani）梭菌（Clostridium 葉梭菌）、破傷風梭菌（Clostrani）梭菌（Clostrani）梭菌（Clostridium）梭菌（Clostrani）梭菌（Clostridium）梭菌（Clostridium）梭菌（Clostridium）（Clostrani）梭菌（Clostrani）。 botulinum）的類毒素疫苗和菌苗類毒素疫苗，以及已在人類廣泛應用的破傷風類毒素疫苗。截至2024年，艱難梭菌疫苗尚未獲得FDA或EMA的批准，因此，預防院內感染是重要的研發方向。

這種需求源自於持續的流行病學需求。世界衛生組織/聯合國兒童基金會估計，2023年全球百白破疫苗第三劑（DTP3）接種率將達到84%，這不僅凸顯了疫苗接種（包括破傷風疫苗）的規模，也反映了疫苗接種不足人口持續存在的差距。在美國，疾病管制與預防中心估計，2017年有223,900人因艱難梭菌感染住院，12,800人死亡，這為預防性創新提供了臨床和經濟上的必要性。在畜牧業，梭菌病仍是持續控制的重點。這是因為孢子會在土壤和農場環境中長期存活，因此接種疫苗是減少突發性損失、保障牲畜福利和增強糧食系統韌性的有效手段。

梭菌疫苗領域的變革性變化

市場正從被動的疾病管理轉向預防性的、基於規範的免疫接種。在畜牧業，多價梭菌疫苗更受青睞，因為土壤傳播的梭菌孢子可以長期存活，而且某些梭狀菌感染一旦出現臨床症狀就會迅速發展。這促使人們重視對牲畜群進行常規疫苗接種、堅持接種加強針以及與獸醫推廣服務機構的協調合作。

人工智慧對梭菌疫苗的累積影響

人工智慧 (AI) 在梭菌疫苗的藥物發現、開發和生命週期管理中發揮著日益重要的作用。 AI 驅動的蛋白質建模、表位預測和免疫資訊學有助於在進行昂貴的實驗室測試之前，優先篩選毒素片段、載體設計和佐劑組合。以艱難梭菌為例，中和毒素 A 和毒素 B 仍然是疫苗設計的核心，這些工具可以在不依賴動物模型和臨床檢驗的情況下，加速候選疫苗的篩檢。

關鍵區域洞察：全球對梭菌疫苗的需求

亞太地區是成長最快的地區之一，這得益於其大規模畜牧養殖體系、不斷擴展的獸醫服務以及日益成長的食品安全期望，該地區涵蓋中國、印度、澳洲、日本和韓國。此外，該地區也受惠於完善的破傷風疫苗公共免疫基礎設施，畜牧業計畫也持續優先進行預防性全群健康管理，以應對快速致命的梭狀梭狀菌感染。北美地區仍然是一個高價值市場，這得益於其先進的伴侶動物和牲畜護理、嚴格的生技藥品監管、完善的低溫運輸系統，以及美國疾病控制與預防中心（CDC）報告的艱難梭菌相關疾病給美國帶來的顯著疾病負擔。

小組對梭菌疫苗策略的關鍵見解

由於商業性家禽、牛、水牛和小反芻動物養殖業的系統化發展，以及各國政府對獸醫保健系統、疾病監測和食品安全體系投入的不斷增加，東協市場正變得日益具有吸引力。海灣合作理事會（GCC）國家對進口生物安全產品、駱駝和小反芻動物健康管理、適應沙漠環境的畜牧系統以及食品安全多元化等方面的需求日益成長。歐盟在品質、藥品安全監測、抗菌藥物的合理使用以及監管要求的協調統一方面一直保持著標竿地位，因此，合規性、批次間一致性以及標籤的合理性是進入歐盟市場的關鍵。

影響梭菌疫苗引入的主要國家趨勢

美國擁有成熟的獸用生技藥品監管體系，但艱難梭菌感染負擔沉重；加拿大則強調畜群健康、食品安全以及在牛、乳牛和伴侶動物通路中分銷高品質生技藥品。墨西哥和巴西是重要的市場，因為它們擁有大規模的牛業，並且需要在以牧場為基礎的養殖系統中保護生產力免受快速致命的梭菌病的侵害。英國、德國、法國、義大利和西班牙將成熟的牲畜疫苗接種實踐與歐洲品質標準、藥物安全監測要求以及支持主導動物健康計畫的抗菌藥物減量政策相結合。

為梭菌疫苗產業的領導者提供的實用建議

行業領導者應優先選擇具有明確免疫持續時間數據、可靠的加強免疫指南、符合實際應用需求的標籤說明以及與常規畜群管理計劃相符的多價梭菌疫苗。生產商應投資於穩定的配方、適合區域市場的包裝規格、低溫運輸安全措施以及經銷商培訓，以提高牛、羊、山羊、馬和伴侶動物的疫苗接種依從性。

基於實證的市場洞察調查方法

本執行摘要基於使用權威來源的二手研究，包括世界衛生組織和聯合國兒童基金會的免疫覆蓋率估計、美國疾病控制與預防中心的感染疾病報告、WOAH動物健康原則、國家獸用生技藥品框架、同行評審的疫苗文獻以及主要組織發布的監管資訊來源。

關於梭菌疫苗未來的結論

對梭菌疫苗的需求得益於已建立的獸醫預防措施、全球破傷風疫苗接種計劃以及持續存在的艱難梭菌感染預防挑戰。市場重視安全、可依需求配製多價疫苗、分銷穩定、並有明確的現場證據支持、具有實用給藥方案和可靠藥物警戒的產品。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 梭菌疫苗市場：依疫苗類型分類

  • 結合疫苗
    • 寡糖結合型
    • 蛋白質結合型
  • 多醣體疫苗
  • 重組疫苗
  • 類毒素疫苗

第8章 梭菌疫苗市場：依目標疾病分類

  • 肉毒桿菌中毒
  • 氣性壞疽
  • 破傷風

第9章 梭菌疫苗市場：依給藥途徑分類

  • 皮內注射
  • 肌肉內部
  • 皮下

第10章 梭菌疫苗市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
    • 電子商務市場
    • 製造商網站
  • 零售藥房

第11章 梭菌疫苗市場：依最終用戶分類

  • 門診部
  • 醫院和診所
  • 公共衛生中心

第12章 梭菌疫苗市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 梭菌疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 梭菌疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Advaxis, Inc.
  • ARKO Laboratories, Inc.
  • Bimeda, Inc.
  • Biogenesis Bago SA
  • Bioveta, as
  • Cadila Healthcare Limited
  • CanFel Therapeutics Inc.
  • Ceva Sante Animale SA
  • China National Biotec Group Co., Ltd.
  • Colorado Serum Company
  • Elanco Animal Health Incorporated
  • Epitopix LLC
  • Genus PLC
  • Hester Biosciences Limited
  • Huvepharma Inc.
  • Hygieia Biological Laboratories
  • IDT Biologika GmbH
  • Indian Immunologicals Limited
  • Laboratorios Hipra SA
  • Merck & Co., Inc.
  • Neogen Corporation
  • Nuovo Biologics, LLC
  • Phibro Animal Health Corporation
  • Tianjin Ringpu Biotechnology Co., Ltd.
  • Valneva SE
  • Vaxxinova International BV
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Services LLC
Product Code: MRR-4311CE1A33B2

The Clostridium Vaccine Market is projected to grow by USD 1,005.91 million at a CAGR of 7.31% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 613.79 million
Estimated Year [2026] USD 660.20 million
Forecast Year [2032] USD 1,005.91 million
CAGR (%) 7.31%

The clostridium vaccine market sits at the intersection of animal health, human immunization, food security, and antimicrobial stewardship. Core products include toxoid and bacterin-toxoid vaccines targeting Clostridium chauvoei, C. perfringens, C. septicum, C. novyi, C. sordellii, C. tetani, and C. botulinum in livestock, alongside established tetanus toxoid use in humans. As of 2024, no C. difficile vaccine had received FDA or EMA approval, keeping hospital-associated disease prevention an important pipeline opportunity.

Demand is supported by durable epidemiological need. WHO/UNICEF estimated global DTP3 coverage at 84% in 2023, underscoring both the scale of tetanus-containing vaccination and the persistent gap among under-immunized populations. In the United States, the CDC estimated 223,900 hospitalized C. difficile cases and 12,800 deaths in 2017, reinforcing the clinical and economic rationale for preventive innovation. In livestock, clostridial diseases remain a persistent control priority because spores can survive in soil and farm environments, making vaccination a practical tool for reducing sudden losses, supporting herd welfare, and strengthening food-system resilience.

Transformative Shifts in the Clostridium Vaccine Landscape

The market is shifting from reactive disease control toward preventive, protocol-driven immunization. In livestock, multivalent clostridial vaccines are preferred because soil-borne spores can persist for long periods and several clostridial diseases progress rapidly once clinical signs appear. This supports routine herd vaccination, booster compliance, and integration with veterinary extension services.

A second shift is the rise of One Health decision-making. Producers, public health authorities, and regulators are aligning vaccination with reduced antimicrobial dependence, safer meat and dairy supply chains, and stronger biosecurity. In human health, the unmet need in C. difficile prevention is redirecting attention from treatment-only strategies to vaccines, monoclonal antibodies, microbiome approaches, and risk-based prevention in older and hospitalized populations. Manufacturing is also evolving toward stronger quality-by-design practices, improved cold-chain visibility, and region-specific distribution models that help maintain vaccine potency from production to point of use.

Cumulative Impact of Artificial Intelligence on Clostridium Vaccines

Artificial intelligence is increasingly shaping clostridium vaccine discovery, development, and lifecycle management. AI-enabled protein modeling, epitope prediction, and immunoinformatics can help prioritize toxin fragments, carrier designs, and adjuvant combinations before costly wet-lab testing. For C. difficile, where toxin A and toxin B neutralization remains central to vaccine design, these tools can accelerate candidate screening while preserving the need for animal models and clinical validation.

AI is also improving manufacturing and market execution. Predictive analytics can support fermentation monitoring, batch consistency, cold-chain planning, inventory allocation, and adverse-event signal detection. The cumulative impact is not a replacement for regulatory evidence; it is a faster, more traceable development environment in which validated algorithms strengthen quality-by-design, pharmacovigilance, and evidence-led deployment across veterinary and human-health settings.

Key Regional Insights Across Global Clostridium Vaccine Demand

Asia-Pacific is a high-priority growth arena because China, India, Australia, Japan, and South Korea combine large livestock systems, expanding veterinary services, and rising food-safety expectations. The region also benefits from broad public immunization infrastructure for tetanus-containing vaccines, while livestock programs continue to emphasize preventive herd health against rapidly fatal clostridial diseases. North America remains a high-value market due to advanced companion animal and livestock care, strong biologics regulation, established cold-chain systems, and the documented U.S. burden of C. difficile-associated disease reported by the CDC.

Latin America is anchored by cattle-intensive markets such as Brazil and Mexico, where clostridial vaccination supports herd productivity, pasture-based livestock systems, and export-oriented animal protein supply chains. Europe benefits from mature veterinary infrastructure, strict biologics quality expectations, and policy emphasis on antimicrobial reduction, which supports vaccine-based prevention in production animals. The Middle East is shaped by livestock import dependence, sheep and goat production, camel health priorities, and biosecurity requirements linked to food-security strategies. Africa presents substantial need because livestock health is closely tied to household income, rural livelihoods, and food security, but cold-chain access and veterinary service coverage remain uneven across countries.

Key Group Insights for Clostridium Vaccine Strategy

ASEAN markets are becoming more attractive as commercial poultry, cattle, buffalo, and small-ruminant production formalizes and governments invest in veterinary capacity, disease surveillance, and food-safety systems. The GCC shows demand linked to import biosecurity, camel and small-ruminant health, desert-adapted livestock systems, and food-security diversification. The European Union remains a benchmark for quality, pharmacovigilance, antimicrobial stewardship, and harmonized regulatory expectations, making compliance, batch consistency, and label evidence central to market access.

BRICS countries represent scale, with China, India, and Brazil offering large livestock populations and Russia and South Africa adding regional disease-control relevance across cattle, sheep, goats, and mixed farming systems. G7 economies shape premium demand, advanced manufacturing standards, and human-health innovation, particularly for C. difficile prevention in aging populations and healthcare-associated infection settings. NATO markets overlap with high-income procurement systems where supply resilience, cold-chain assurance, emergency preparedness, and trusted biologics quality are increasingly important for both public-health and animal-health planning.

Key Country Insights Shaping Clostridium Vaccine Adoption

The United States is defined by mature veterinary biologics oversight and a measurable C. difficile burden, while Canada emphasizes herd health, food safety, and high-quality biologics distribution across cattle, dairy, and companion animal channels. Mexico and Brazil are important due to cattle production and the need to protect productivity against rapidly fatal clostridial diseases in pasture-based systems. The United Kingdom, Germany, France, Italy, and Spain combine established livestock vaccination practices with European quality expectations, pharmacovigilance requirements, and antimicrobial-reduction policies that favor prevention-led animal health programs.

Russia remains relevant through cattle and small-ruminant vaccination needs across diverse climatic and production conditions, while China and India offer scale across livestock production, public immunization infrastructure, and expanding veterinary service networks. Japan and South Korea represent quality-sensitive markets with advanced veterinary services, strong cold-chain expectations, and high regulatory scrutiny. Australia is strategically important because of its export-oriented cattle and sheep industries, where clostridial vaccination is embedded in preventive herd health programs and supports animal welfare, productivity, and international trade confidence.

Actionable Recommendations for Clostridium Vaccine Leaders

Industry leaders should prioritize multivalent animal clostridial vaccines with clear duration-of-immunity data, reliable booster guidance, field-relevant labeling, and compatibility with routine herd management calendars. Manufacturers should invest in stable formulations, regional packaging sizes, cold-chain safeguards, and distributor education to improve compliance in cattle, sheep, goats, horses, and companion animals.

For human-health pipelines, developers should focus C. difficile vaccine development on high-risk populations, including older adults and patients with recurrent healthcare exposure, while aligning trial design with clinically meaningful prevention endpoints and regulatory expectations. Across both human and veterinary segments, leaders should use validated AI, real-world safety monitoring, resilient supply partnerships, and practical training for vaccinators to improve development speed and adoption without weakening regulatory credibility.

Research Methodology for Evidence-Based Market Insights

This executive summary is built from secondary research using authoritative sources, including WHO and UNICEF immunization coverage estimates, CDC infectious disease reporting, WOAH animal-health principles, national veterinary biologics frameworks, peer-reviewed vaccine literature, and publicly available regulatory information from major agencies.

The analysis applies source triangulation across epidemiology, vaccination policy, animal-production systems, clinical unmet need, biologics manufacturing practices, cold-chain requirements, and regional regulatory environments. No unsupported market-size claims or speculative approval assumptions are used; insights are limited to evidence-based demand drivers, verified disease burden indicators, established immunization practices, and observable shifts in vaccine development and distribution.

Conclusion on the Future of Clostridium Vaccines

Clostridium vaccine demand is sustained by a combination of established veterinary prevention, global tetanus immunization, and the unresolved challenge of C. difficile prevention. The market rewards products that are safe, multivalent where appropriate, stable in distribution, and supported by clear field evidence, practical dosing schedules, and credible pharmacovigilance.

Future competitiveness will depend on balancing scientific innovation with practical access. Organizations that combine validated antigen design, reliable manufacturing, regional regulatory fluency, cold-chain discipline, and education-led adoption will be best positioned to serve livestock producers, healthcare systems, and public-health stakeholders.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Clostridium Vaccine Market, by Vaccine Type

  • 7.1. Conjugate Vaccine
    • 7.1.1. Oligosaccharide-Conjugated
    • 7.1.2. Protein-Conjugated
  • 7.2. Polysaccharide Vaccine
  • 7.3. Recombinant Vaccine
  • 7.4. Toxoid Vaccine

8. Clostridium Vaccine Market, by Target Disease

  • 8.1. Botulism
  • 8.2. Gas Gangrene
  • 8.3. Tetanus

9. Clostridium Vaccine Market, by Route Of Administration

  • 9.1. Intradermal
  • 9.2. Intramuscular
  • 9.3. Subcutaneous

10. Clostridium Vaccine Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
    • 10.2.1. E-Commerce Marketplaces
    • 10.2.2. Manufacturer Websites
  • 10.3. Retail Pharmacies

11. Clostridium Vaccine Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Hospitals & Clinics
  • 11.3. Public Health Centers

12. Clostridium Vaccine Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Clostridium Vaccine Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Clostridium Vaccine Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Advaxis, Inc.
  • 16.2. ARKO Laboratories, Inc.
  • 16.3. Bimeda, Inc.
  • 16.4. Biogenesis Bago S.A.
  • 16.5. Bioveta, a.s.
  • 16.6. Cadila Healthcare Limited
  • 16.7. CanFel Therapeutics Inc.
  • 16.8. Ceva Sante Animale S.A.
  • 16.9. China National Biotec Group Co., Ltd.
  • 16.10. Colorado Serum Company
  • 16.11. Elanco Animal Health Incorporated
  • 16.12. Epitopix LLC
  • 16.13. Genus PLC
  • 16.14. Hester Biosciences Limited
  • 16.15. Huvepharma Inc.
  • 16.16. Hygieia Biological Laboratories
  • 16.17. IDT Biologika GmbH
  • 16.18. Indian Immunologicals Limited
  • 16.19. Laboratorios Hipra S.A.
  • 16.20. Merck & Co., Inc.
  • 16.21. Neogen Corporation
  • 16.22. Nuovo Biologics, LLC
  • 16.23. Phibro Animal Health Corporation
  • 16.24. Tianjin Ringpu Biotechnology Co., Ltd.
  • 16.25. Valneva SE
  • 16.26. Vaxxinova International B.V.
  • 16.27. Vetoquinol S.A.
  • 16.28. Virbac S.A.
  • 16.29. Zoetis Services LLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL CLOSTRIDIUM VACCINE MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CLOSTRIDIUM VACCINE MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CLOSTRIDIUM VACCINE MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CLOSTRIDIUM VACCINE MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CLOSTRIDIUM VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CLOSTRIDIUM VACCINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL CLOSTRIDIUM VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL CLOSTRIDIUM VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CLOSTRIDIUM VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CLOSTRIDIUM VACCINE MARKET SIZE, BY TARGET DISEASE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CLOSTRIDIUM VACCINE MARKET SIZE, BY TARGET DISEASE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CLOSTRIDIUM VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CLOSTRIDIUM VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CLOSTRIDIUM VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CLOSTRIDIUM VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CLOSTRIDIUM VACCINE MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CLOSTRIDIUM VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CLOSTRIDIUM VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CLOSTRIDIUM VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CLOSTRIDIUM VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CLOSTRIDIUM VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CLOSTRIDIUM VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL CLOSTRIDIUM VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CLOSTRIDIUM VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CLOSTRIDIUM VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL OLIGOSACCHARIDE-CONJUGATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OLIGOSACCHARIDE-CONJUGATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OLIGOSACCHARIDE-CONJUGATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PROTEIN-CONJUGATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PROTEIN-CONJUGATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PROTEIN-CONJUGATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL POLYSACCHARIDE VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL POLYSACCHARIDE VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL POLYSACCHARIDE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RECOMBINANT VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RECOMBINANT VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RECOMBINANT VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TOXOID VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TOXOID VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CLOSTRIDIUM VACCINE MARKET SIZE, BY TARGET DISEASE, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BOTULISM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BOTULISM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BOTULISM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GAS GANGRENE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GAS GANGRENE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GAS GANGRENE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TETANUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TETANUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TETANUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CLOSTRIDIUM VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INTRADERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTRADERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INTRADERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CLOSTRIDIUM VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL E-COMMERCE MARKETPLACES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL E-COMMERCE MARKETPLACES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL E-COMMERCE MARKETPLACES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MANUFACTURER WEBSITES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MANUFACTURER WEBSITES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MANUFACTURER WEBSITES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CLOSTRIDIUM VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PUBLIC HEALTH CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PUBLIC HEALTH CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PUBLIC HEALTH CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CLOSTRIDIUM VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC CLOSTRIDIUM VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC CLOSTRIDIUM VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC CLOSTRIDIUM VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC CLOSTRIDIUM VACCINE MARKET SIZE, BY TARGET DISEASE, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC CLOSTRIDIUM VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC CLOSTRIDIUM VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC CLOSTRIDIUM VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC CLOSTRIDIUM VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA CLOSTRIDIUM VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA CLOSTRIDIUM VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA CLOSTRIDIUM VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA CLOSTRIDIUM VACCINE MARKET SIZE, BY TARGET DISEASE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA CLOSTRIDIUM VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA CLOSTRIDIUM VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA CLOSTRIDIUM VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA CLOSTRIDIUM VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA CLOSTRIDIUM VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA CLOSTRIDIUM VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA CLOSTRIDIUM VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA CLOSTRIDIUM VACCINE MARKET SIZE, BY TARGET DISEASE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA CLOSTRIDIUM VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA CLOSTRIDIUM VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA CLOSTRIDIUM VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA CLOSTRIDIUM VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE CLOSTRIDIUM VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE CLOSTRIDIUM VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE CLOSTRIDIUM VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE CLOSTRIDIUM VACCINE MARKET SIZE, BY TARGET DISEASE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE CLOSTRIDIUM VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE CLOSTRIDIUM VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE CLOSTRIDIUM VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE CLOSTRIDIUM VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST CLOSTRIDIUM VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST CLOSTRIDIUM VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST CLOSTRIDIUM VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST CLOSTRIDIUM VACCINE MARKET SIZE, BY TARGET DISEASE, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST CLOSTRIDIUM VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST CLOSTRIDIUM VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST CLOSTRIDIUM VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST CLOSTRIDIUM VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA CLOSTRIDIUM VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA CLOSTRIDIUM VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA CLOSTRIDIUM VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA CLOSTRIDIUM VACCINE MARKET SIZE, BY TARGET DISEASE, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA CLOSTRIDIUM VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA CLOSTRIDIUM VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA CLOSTRIDIUM VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA CLOSTRIDIUM VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CLOSTRIDIUM VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN CLOSTRIDIUM VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN CLOSTRIDIUM VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN CLOSTRIDIUM VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN CLOSTRIDIUM VACCINE MARKET SIZE, BY TARGET DISEASE, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN CLOSTRIDIUM VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN CLOSTRIDIUM VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN CLOSTRIDIUM VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN CLOSTRIDIUM VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. GCC CLOSTRIDIUM VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 126. GCC CLOSTRIDIUM VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. GCC CLOSTRIDIUM VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 128. GCC CLOSTRIDIUM VACCINE MARKET SIZE, BY TARGET DISEASE, 2018-2032 (USD MILLION)
  • TABLE 129. GCC CLOSTRIDIUM VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. GCC CLOSTRIDIUM VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. GCC CLOSTRIDIUM VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 132. GCC CLOSTRIDIUM VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION CLOSTRIDIUM VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION CLOSTRIDIUM VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION CLOSTRIDIUM VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION CLOSTRIDIUM VACCINE MARKET SIZE, BY TARGET DISEASE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION CLOSTRIDIUM VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION CLOSTRIDIUM VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION CLOSTRIDIUM VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION CLOSTRIDIUM VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS CLOSTRIDIUM VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS CLOSTRIDIUM VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS CLOSTRIDIUM VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS CLOSTRIDIUM VACCINE MARKET SIZE, BY TARGET DISEASE, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS CLOSTRIDIUM VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS CLOSTRIDIUM VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS CLOSTRIDIUM VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS CLOSTRIDIUM VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. G7 CLOSTRIDIUM VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 150. G7 CLOSTRIDIUM VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. G7 CLOSTRIDIUM VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 152. G7 CLOSTRIDIUM VACCINE MARKET SIZE, BY TARGET DISEASE, 2018-2032 (USD MILLION)
  • TABLE 153. G7 CLOSTRIDIUM VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. G7 CLOSTRIDIUM VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. G7 CLOSTRIDIUM VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 156. G7 CLOSTRIDIUM VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. NATO CLOSTRIDIUM VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. NATO CLOSTRIDIUM VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. NATO CLOSTRIDIUM VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 160. NATO CLOSTRIDIUM VACCINE MARKET SIZE, BY TARGET DISEASE, 2018-2032 (USD MILLION)
  • TABLE 161. NATO CLOSTRIDIUM VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. NATO CLOSTRIDIUM VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. NATO CLOSTRIDIUM VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 164. NATO CLOSTRIDIUM VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL CLOSTRIDIUM VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES CLOSTRIDIUM VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES CLOSTRIDIUM VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES CLOSTRIDIUM VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES CLOSTRIDIUM VACCINE MARKET SIZE, BY TARGET DISEASE, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES CLOSTRIDIUM VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES CLOSTRIDIUM VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES CLOSTRIDIUM VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES CLOSTRIDIUM VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. CANADA CLOSTRIDIUM VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 175. CANADA CLOSTRIDIUM VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. CANADA CLOSTRIDIUM VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 177. CANADA CLOSTRIDIUM VACCINE MARKET SIZE, BY TARGET DISEASE, 2018-2032 (USD MILLION)
  • TABLE 178. CANADA CLOSTRIDIUM VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. CANADA CLOSTRIDIUM VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. CANADA CLOSTRIDIUM VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 181. CANADA CLOSTRIDIUM VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. MEXICO CLOSTRIDIUM VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. MEXICO CLOSTRIDIUM VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. MEXICO CLOSTRIDIUM VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 185. MEXICO CLOSTRIDIUM VACCINE MARKET SIZE, BY TARGET DISEASE, 2018-2032 (USD MILLION)
  • TABLE 186. MEXICO CLOSTRIDIUM VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. MEXICO CLOSTRIDIUM VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. MEXICO CLOSTRIDIUM VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 189. MEXICO CLOSTRIDIUM VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. BRAZIL CLOSTRIDIUM VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. BRAZIL CLOSTRIDIUM VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. BRAZIL CLOSTRIDIUM VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 193. BRAZIL CLOSTRIDIUM VACCINE MARKET SIZE, BY TARGET DISEASE, 2018-2032 (USD MILLION)
  • TABLE 194. BRAZIL CLOSTRIDIUM VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. BRAZIL CLOSTRIDIUM VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. BRAZIL CLOSTRIDIUM VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 197. BRAZIL CLOSTRIDIUM VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED KINGDOM CLOSTRIDIUM VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED KINGDOM CLOSTRIDIUM VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED KINGDOM CLOSTRIDIUM VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED KINGDOM CLOSTRIDIUM VACCINE MARKET SIZE, BY TARGET DISEASE, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED KINGDOM CLOSTRIDIUM VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED KINGDOM CLOSTRIDIUM VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED KINGDOM CLOSTRIDIUM VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED KINGDOM CLOSTRIDIUM VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. GERMANY CLOSTRIDIUM VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. GERMANY CLOSTRIDIUM VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. GERMANY CLOSTRIDIUM VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 209. GERMANY CLOSTRIDIUM VACCINE MARKET SIZE, BY TARGET DISEASE, 2018-2032 (USD MILLION)
  • TABLE 210. GERMANY CLOSTRIDIUM VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. GERMANY CLOSTRIDIUM VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. GERMANY CLOSTRIDIUM VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 213. GERMANY CLOSTRIDIUM VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. FRANCE CLOSTRIDIUM VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. FRANCE CLOSTRIDIUM VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. FRANCE CLOSTRIDIUM VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 217. FRANCE CLOSTRIDIUM VACCINE MARKET SIZE, BY TARGET DISEASE, 2018-2032 (USD MILLION)
  • TABLE 218. FRANCE CLOSTRIDIUM VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. FRANCE CLOSTRIDIUM VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. FRANCE CLOSTRIDIUM VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 221. FRANCE CLOSTRIDIUM VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. RUSSIA CLOSTRIDIUM VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 223. RUSSIA CLOSTRIDIUM VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. RUSSIA CLOSTRIDIUM VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 225. RUSSIA CLOSTRIDIUM VACCINE MARKET SIZE, BY TARGET DISEASE, 2018-2032 (USD MILLION)
  • TABLE 226. RUSSIA CLOSTRIDIUM VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 227. RUSSIA CLOSTRIDIUM VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. RUSSIA CLOSTRIDIUM VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 229. RUSSIA CLOSTRIDIUM VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. ITALY CLOSTRIDIUM VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. ITALY CLOSTRIDIUM VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. ITALY CLOSTRIDIUM VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 233. ITALY CLOSTRIDIUM VACCINE MARKET SIZE, BY TARGET DISEASE, 2018-2032 (USD MILLION)
  • TABLE 234. ITALY CLOSTRIDIUM VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. ITALY CLOSTRIDIUM VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. ITALY CLOSTRIDIUM VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 237. ITALY CLOSTRIDIUM VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. SPAIN CLOSTRIDIUM VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. SPAIN CLOSTRIDIUM VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. SPAIN CLOSTRIDIUM VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 241. SPAIN CLOSTRIDIUM VACCINE MARKET SIZE, BY TARGET DISEASE, 2018-2032 (USD MILLION)
  • TABLE 242. SPAIN CLOSTRIDIUM VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. SPAIN CLOSTRIDIUM VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. SPAIN CLOSTRIDIUM VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 245. SPAIN CLOSTRIDIUM VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA CLOSTRIDIUM VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA CLOSTRIDIUM VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA CLOSTRIDIUM VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA CLOSTRIDIUM VACCINE MARKET SIZE, BY TARGET DISEASE, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA CLOSTRIDIUM VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA CLOSTRIDIUM VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA CLOSTRIDIUM VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA CLOSTRIDIUM VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. INDIA CLOSTRIDIUM VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. INDIA CLOSTRIDIUM VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. INDIA CLOSTRIDIUM VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 257. INDIA CLOSTRIDIUM VACCINE MARKET SIZE, BY TARGET DISEASE, 2018-2032 (USD MILLION)
  • TABLE 258. INDIA CLOSTRIDIUM VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 259. INDIA CLOSTRIDIUM VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 260. INDIA CLOSTRIDIUM VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 261. INDIA CLOSTRIDIUM VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. JAPAN CLOSTRIDIUM VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. JAPAN CLOSTRIDIUM VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. JAPAN CLOSTRIDIUM VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 265. JAPAN CLOSTRIDIUM VACCINE MARKET SIZE, BY TARGET DISEASE, 2018-2032 (USD MILLION)
  • TABLE 266. JAPAN CLOSTRIDIUM VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 267. JAPAN CLOSTRIDIUM VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 268. JAPAN CLOSTRIDIUM VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 269. JAPAN CLOSTRIDIUM VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. AUSTRALIA CLOSTRIDIUM VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 271. AUSTRALIA CLOSTRIDIUM VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. AUSTRALIA CLOSTRIDIUM VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 273. AUSTRALIA CLOSTRIDIUM VACCINE MARKET SIZE, BY TARGET DISEASE, 2018-2032 (USD MILLION)
  • TABLE 274. AUSTRALIA CLOSTRIDIUM VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 275. AUSTRALIA CLOSTRIDIUM VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 276. AUSTRALIA CLOSTRIDIUM VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 277. AUSTRALIA CLOSTRIDIUM VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. SOUTH KOREA CLOSTRIDIUM VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 279. SOUTH KOREA CLOSTRIDIUM VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. SOUTH KOREA CLOSTRIDIUM VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 281. SOUTH KOREA CLOSTRIDIUM VACCINE MARKET SIZE, BY TARGET DISEASE, 2018-2032 (USD MILLION)
  • TABLE 282. SOUTH KOREA CLOSTRIDIUM VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 283. SOUTH KOREA CLOSTRIDIUM VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 284. SOUTH KOREA CLOSTRIDIUM VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 285. SOUTH KOREA CLOSTRIDIUM VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)